TRANBERG Thermal Therapy System developer Clinical Laserthermia Systems AB (publ) (STO:CLS-B) announced on Thursday that it has received additional orders from ClearPoint Neuro, Inc (Nasdaq:CLPT), a medical device company, valued at approximately SEK7.5m.
These orders are for ClearPoint Prism products as part of ClearPoint Neuro's North American market launch initiated in early June this year. This follows previous orders totaling approximately SEK10.5m received around the turn of the year 2023/2024.
CLS and ClearPoint Neuro aim to develop and commercialize a next-generation, fully integrated laser therapy system for high-precision MRI-guided stereotactic laser ablation in neurosurgery. The integrated product solution offers streamlined workflows for identifying, navigating and positioning sterile laser applicators in target tissues, with MRI-guided monitoring and control of temperature and ablation progress.
Recent strategic steps include obtaining US-FDA 510(k) clearance for ClearPoint Neuro's Prism Bone Anchor Accessory, further strengthening the product offering and expanding the market in the US.
(EUR1=SEK11.19)
FDA grants priority review for GSK's gepotidacin gonorrhoea indication
RemeGen receives FDA approval to advance RC148 into Phase II trials for solid tumours
FDA lifts pause on Valneva's chikungunya vaccine IXCHIQ for elderly, updates prescribing information
Jazz Pharmaceuticals' Modeyso approved by US FDA for H3 K27M-mutant diffuse midline glioma treatment
Freenome and Exact Sciences agree licensing deal for CRC blood test
Intas Pharmaceuticals and Accord BioPharma acquire UDENYCA (pegfilgrastim-cbqv)
FDA approves Teva's AJOVY for paediatric episodic migraine prevention
Galapagos receives FDA RMAT designation for CAR-T therapy in mantle cell lymphoma